Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA

Br J Pharmacol. 2001 Apr;132(7):1467-76. doi: 10.1038/sj.bjp.0703963.

Abstract

1. This study was designed to assess the molecular and cellular events involved in the up-regulation (and receptor supersensitivity) of brain alpha(2)-adrenoceptors as a result of chronic depletion of noradrenaline (and other monoamines) by reserpine. 2. Chronic reserpine (0.25 mg kg(-1) s.c., every 48 h for 6 - 14 days) increased significantly the density (B(max) values) of cortical alpha(2)-adrenoceptor agonist sites (34 - 48% for [(3)H]-UK14304, 22 - 32% for [(3)H]-clonidine) but not that of antagonist sites (11 - 18% for [(3)H]-RX821002). Competition of [(3)H]-RX821002 binding by (-)-adrenaline further indicated that chronic reserpine was associated with up-regulation of the high-affinity state of alpha(2)-adrenoceptors. 3. In cortical membranes of reserpine-treated rats (0.25 mg kg(-1) s.c., every 48 h for 20 days), the immunoreactivities of various G proteins (Galphai(1/2), Galphai(3), Galphao and Galphas) were increased (25 - 34%). Because the high-affinity conformation of the alpha(2)-adrenoceptor is most probably related to the complex with Galphai(2) proteins, these results suggested an increase in signal transduction through alpha(2)-adrenoceptors (and other monoamine receptors) induced by chronic reserpine. 4. After alpha(2)-adrenoceptor alkylation, the analysis of receptor recovery (B(max) for [(3)H]-UK14304) indicated that the increased density of cortical alpha(2)-adrenoceptors in reserpine-treated rats was probably due to a higher appearance rate constant of the receptor ((Delta)r=57%) and not to a decreased disappearance rate constant ((Delta)k=7%). 5. Northern- and dot-blot analyses of RNA extracted from the cerebral cortex of saline- and reserpine-treated rats (0.25 mg kg(-1), s.c., every 48 h for 20 days) revealed that reserpine markedly increased the expression of alpha(2a)-adrenoceptor mRNA in the brain (125%). This transcriptional activation of the receptor gene expression appears to be the cellular mechanism by which reserpine induces up-regulation in the density of brain alpha(2)-adrenoceptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Binding, Competitive / drug effects
  • Brain / drug effects
  • Brain / metabolism*
  • Brimonidine Tartrate
  • Clonidine / metabolism
  • Dose-Response Relationship, Drug
  • Epinephrine / pharmacology
  • GTP-Binding Proteins / metabolism
  • Gene Expression Regulation / drug effects
  • Idazoxan / analogs & derivatives*
  • Idazoxan / metabolism
  • Male
  • Membranes / metabolism
  • Norepinephrine / metabolism*
  • Quinolines / pharmacology
  • Quinoxalines / metabolism
  • RNA, Messenger / drug effects
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-2 / drug effects
  • Receptors, Adrenergic, alpha-2 / genetics
  • Receptors, Adrenergic, alpha-2 / metabolism*
  • Reserpine / pharmacology
  • Tritium

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic alpha-Antagonists
  • Quinolines
  • Quinoxalines
  • RNA, Messenger
  • Receptors, Adrenergic, alpha-2
  • Tritium
  • Brimonidine Tartrate
  • EEDQ
  • Reserpine
  • 2-methoxyidazoxan
  • GTP-Binding Proteins
  • Clonidine
  • Norepinephrine
  • Idazoxan
  • Epinephrine